IceCure Medical Ltd (NASDAQ:ICCM) Sees Large Drop in Short Interest

IceCure Medical Ltd (NASDAQ:ICCM) saw a significant decline in short interest in February. As of February 28th, there was short interest totalling 598,100 shares, a decline of 22.7% from the February 13th total of 773,300 shares. Currently, 2.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 385,300 shares, the short-interest ratio is currently 1.6 days.

IceCure Medical Price Performance

Shares of NASDAQ:ICCM traded down $0.05 during mid-day trading on Tuesday, reaching $1.47. The stock had a trading volume of 399,948 shares, compared to its average volume of 512,538. The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02. The company has a market cap of $81.59 million, a P/E ratio of -5.07 and a beta of 0.37. IceCure Medical has a 1 year low of $0.48 and a 1 year high of $1.66. The business’s 50 day moving average price is $1.32 and its 200 day moving average price is $0.96.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.50 target price on shares of IceCure Medical in a research report on Wednesday, November 27th.

Institutional Investors Weigh In On IceCure Medical

An institutional investor recently raised its position in IceCure Medical stock. Geode Capital Management LLC boosted its stake in shares of IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 40,453 shares of the company’s stock after acquiring an additional 14,893 shares during the quarter. Geode Capital Management LLC owned about 0.07% of IceCure Medical worth $44,000 as of its most recent SEC filing. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.